Pharmaceutical AstraZeneca reported that the production of 50 million doses of the vaccine against COVID-19 in the country.
The manufacture of the vaccine was done in alliance with different commercial partners in the region, including Liomont, Mexican laboratory where the vaccine filling and packaging process is carried out.
Sylvia Varela, vice president for Latin America at AstraZeneca, highlighted that the company is committed to changing the course of the pandemic with a vaccine made for the world, produced in Mexico.
“Our priority is to protect the health of Latin Americans. Industry, governments and international organizations must work together in the fight against this pandemic“Varela said in a statement.
The AstraZeneca dosage has been shown to be generally well tolerated and effective in clinical studies of up to 60,000 participants and highly effective across all degrees of disease severity, with consistent efficacy across demographic, ethnic, and age groups, as well as 100% protection against severe cases, hospitalization, and death, more than 21 days after the first dose.
Inoculation is also effective against all current SARS-CoV-2 variants of concern, and thus far remains effective against hospitalization for more than 20 weeks after a second dose of the vaccine. The vaccine has also been shown to be effective in real life in Latin America, including Chile and Brazil.
To date, 1.5 billion doses of AstraZeneca’s vaccine have been released for supply in more than 170 countries and represent approximately two-thirds of COVAX supply, to date.